Article Information
- Received September 6, 2008
- Revision received November 1, 2009
- Accepted November 4, 2009
- First published January 13, 2010.
- Version of record published January 13, 2010.
Author Information
- Jason A. Bartos1,
- Jason D. Ulrich1,
- Hongbin Li3,
- Michael A. Beazely3,
- Yucui Chen1,
- John F. MacDonald3,4, and
- Johannes W. Hell1,2
- 1Department of Pharmacology, Roy J. and Lucille A. Carver College of Medicine, University of Iowa, Iowa City, Iowa 52242-1109,
- 2Department of Pharmacology, University of California, Davis, Davis, California 95616-8636,
- 3Department of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada, and
- 4Robarts Research Institute, University of Western Ontario, London, Ontario N6A 5K8, Canada
- Correspondence should be addressed to Johannes W. Hell, Department of Pharmacology, School of Medicine, University of California at Davis, GBSF 3503, 451 East Health Sciences Drive, Davis, CA 95616-8636. jwhell{at}ucdavis.edu
Author contributions
Disclosures
- Received September 6, 2008.
- Revision received November 1, 2009.
- Accepted November 4, 2009.
This work was supported by National Institutes of Health (NIH) Grants R01 NS046450 and R01 NS035563 (J.W.H.), Canadian Institutes of Health Research (CIHR) Grant 44008 (J.F.M.), NIH Predoctoral Training Grant T32 GM008365 (J.A.B., J.D.U.), American Heart Association Predoctoral Fellowship 0515567Z (J.A.B.), NIH National Research Service Award F31 MH081420 (J.D.U.), and a CIHR postdoctoral award (M.A.B.). Parental viral vectors were provided and FIV viruses produced by the University of Iowa Center for Gene Therapy for Cystic Fibrosis, which is supported by NIH Grant P30 DK54759. We thank Drs. L. M. Graves and H. S. Earp (University of North Carolina at Chapel Hill, Chapel Hill, NC) for the N- and C-terminal Pyk2 antibodies, Dr. P. DeCamilli (Yale University, New Haven, CT) for the anti-synapsin antibody, Dr. M. A. Shea (University of Iowa, Iowa City, IA) for purified calmodulin, Dr. S. Strack for the PC6-3 cell line, and Drs. J. C. Houtman (University of Iowa, Iowa City, IA) and Lee M. Graves (University of North Carolina at Chapel Hill, Chapel Hill, NC) for critically reading this manuscript.
- Correspondence should be addressed to Johannes W. Hell, Department of Pharmacology, School of Medicine, University of California at Davis, GBSF 3503, 451 East Health Sciences Drive, Davis, CA 95616-8636. jwhell{at}ucdavis.edu
Online Impact